CAPTURE: CIRCULATING TUMOUR DNA ASSESSMENT OF PIK3CA TO GUIDE TREATMENT RESPONSE
Grant number: 1143025 | Funding period: 2018 - 2023
Many breast cancers shed small amounts of DNA (called circulating tumor DNA or ctDNA) into the patient’s bloodstream. This proposal is for a clinical trial which will examine the use of ctDNA to follow levels of a specific therapeutic target (a mutation in a gene called PIK3CA) in blood, to allow the timely introduction of a targeted therapy (PI3K inhibitor). The trial aims to lead to improved outcomes for women with estrogen receptor positive metastatic breast cancer.